Other examples for TRPML1 activation providing potential therapeutic benefit in neurodegenerative or lysosomal storage diseases are HIV gp120-related lysosomal storage, where TRPML1 activation cleared amyloid β (Aβ) from lysosomal compartments in neurons1175, and data suggesting TRPML1 activation to promote autophagy, facilitating the clearance of accumulated α-synuclein in both in vitro and in vivo models of MPP+/MPTP-induced Parkinson's disease.1176. Here, MCOLN1 is linked to lysosomal storage disease.